Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
205.82B
Market cap205.82B
Price-Earnings ratio
10.44
Price-Earnings ratio10.44
Dividend yield
2.76%
Dividend yield2.76%
Average volume
11.87M
Average volume11.87M
High today
$46.05
High today$46.05
Low today
$44.00
Low today$44.00
Open price
$44.03
Open price$44.03
Volume
7.32M
Volume7.32M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Seeking Alpha 33m
France to become first EU nation to cover weight-loss meds

France has become the first EU nation to reimburse weight loss medications, including blockbuster GLP-1s from Novo Nordisk (NVO) and Eli Lilly (LLY), with cover...

France to become first EU nation to cover weight-loss meds
CNBC 5h
CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. CVS Health on Thursday said it will re...

CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
Simply Wall St 8h
Novo Nordisk Advances Oral Wegovy Lead As Investor Focus Shifts To Uptake

Novo Nordisk (NYSE:NVO) has gained a lead in oral anti obesity pills with its oral Wegovy following a positive opinion from the European Medicines Agency. Earl...

Novo Nordisk Advances Oral Wegovy Lead As Investor Focus Shifts To Uptake

Analyst ratings

57%

of 37 ratings
Buy
35.1%
Hold
56.8%
Sell
8.1%

More NVO News

The Motley Fool 19h
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?

Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly...

Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried?
TipRanks 23h
Novo Nordisk to showcase new data from its cardiometabolic portfolio at ADA

The company states: “Novo Nordisk (NVO) announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientifi...

TipRanks 1d
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Nasdaq 2d
Prediction: These 2 Obesity Drug Stocks Could Double in 2026

Key Points The weight loss opportunity is a significant one for companies and investors -- and companies involved have seen their shares soar. Analysts predic...

Prediction: These 2 Obesity Drug Stocks Could Double in 2026
The Motley Fool 3d
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

The introduction of GLP-1 drugs has revolutionized the way the world looks at weight loss. Taking a shot or a pill to curb one's appetite and lose weight is clo...

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro
Nasdaq 3d
CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has issued a positive opinio...

CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity
Simply Wall St 5d
Assessing Novo Nordisk Valuation After Recent Share Price Volatility

Advertisement Recent performance snapshot Novo Nordisk (NYSE:NVO) has drawn attention after a mixed run in the stock, with a gain of about 15% over the past m...

Assessing Novo Nordisk Valuation After Recent Share Price Volatility

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.